Overview: HLA CBZ Phenytoin Hypersensitivity TestIntroduction: The HLA CBZ Phenytoin Hypersensitivity Test detects HLA-B1502 to assess carbamazepine or phenytoin hypersensitivity risk, preventing severe reactions. Aligned with 2023 CPIC guidelines, it uses PCR for high specificity, supporting drug sensitivity screening. This test is critical for guiding safe anticonvulsant therapy, avoiding severe cutaneous reactions, and improving outcomes in pharmacogenomics for patients with epilepsy or neuropathic pain.Other Names: HLA-B1502 Assay, Carbamazepine/Phenytoin Sensitivity Test.FDA Status: Laboratory-developed test (LDT), meeting pharmacogenomics standards for diagnostic accuracy.Historical Milestone: HLA-B1502 testing began in the 2000s after carbamazepine hypersensitivity was linked to this allele. PCR-based assays improved screening accuracy.Purpose: Assesses HLA-B1502 for carbamazepine/phenytoin hypersensitivity risk, guides safe therapy, and prevents severe reactions in patients with epilepsy or pain.Test Parameters: 1. HLA-B15:02Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of epilepsy, drug allergies, or family history of hypersensitivity.Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.Sample Stability at Room Temperature: 24 hoursSample Stability at Refrigeration: 48 hoursSample Stability at Frozen: Not frozenMedical History: Document history of epilepsy, neuropathic pain, drug allergies, or family history of hypersensitivity reactions. Include current medications, especially anticonvulsants.Consent: Written consent required, detailing the tests purpose, hypersensitivity implications, and potential need for alternative therapy.Procedural Considerations: Uses PCR to detect HLA-B1502. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often before carbamazepine or phenytoin initiation.Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.Clinical Significance: Positive HLA-B1502 indicates high carbamazepine/phenytoin hypersensitivity risk, prompting alternative therapy (e.g., lamotrigine). Negative results suggest safe use but require monitoring.Specialist Consultation: Consult a neurologist or pharmacogenomicist for result interpretation and therapy planning.Additional Supporting Tests: EEG, liver function tests, or skin patch testing to assess epilepsy and drug sensitivity.Test Limitations: Limited to HLA-B1502; other hypersensitivity causes may exist. Clinical correlation is needed.References: CPIC Anticonvulsant Guidelines, 2023; Clinical Pharmacogenetics, Chen P, 2022.